Robert L. Myers
Net Worth

Last updated:

What is Robert L. Myers net worth?

The estimated net worth of Mr. Robert L. Myers is at least $3,998,219 as of 25 Sep 2023. He owns shares worth $64,139 as insider and has received compensation worth at least $3,934,080 in Predictive Oncology Inc..

What is the salary of Robert L. Myers?

Mr. Robert L. Myers salary is $327,840 per year as Chief Financial Officer & Sec. in Predictive Oncology Inc..

How old is Robert L. Myers?

Mr. Robert L. Myers is 70 years old, born in 1955.

What stocks does Robert L. Myers currently own?

As insider, Mr. Robert L. Myers owns shares in one company:

Company Title Shares Price per share Total value
Predictive Oncology Inc. (POAI) Chief Financial Officer & Sec. 71,265 $0.9 $64,139

What does Predictive Oncology Inc. do?

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

POAI logo
POAI
Predictive Oncology Inc.
$0.9

Robert L. Myers insider trading

Predictive Oncology Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 1,667 N/A N/A
Purchase
Common Stock 8,795 $0.57 $5,004
Option
Common Stock 33,333 N/A N/A
Option
Restricted Stock Units 33,333 N/A N/A
Purchase
Common Stock 16,125 $0.3 $4,886
Option
Common Stock, $.01 par value 33,334 $1.13 $37,667
Option
Restricted Stock Units 33,334 N/A N/A
Option
Common Stock 15,685 N/A N/A
Option
Stock Options (right to buy) 15,685 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 5,000 N/A N/A
Purchase
Common Stock 6,250 N/A N/A

Predictive Oncology key executives

Predictive Oncology Inc. executives and other stock owners filed with the SEC: